Real-world treatment practices of selexipag and parenteral prostacyclin (PGI2) analogs for pulmonary arterial hypertension in Japan: Retrospective study of the Japan PH registry
{{output}}
Background: In treatment of pulmonary arterial hypertension (PAH), the prostacyclin (PGI2) pathway is targeted by oral selexipag and parenteral PGI2 analogs. Although guidelines recommend therapeutic strategies based on disease s... ...
